Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer

被引：3

作者：

Yuan, Yang ^{[1
]}

Zhang, Shaohua ^{[2
]}

Wang, Tao ^{[1
]}

Bian, Li ^{[2
]}

Yan, Min ^{[3
,4
]}

Yin, Yongmei ^{[5
,6
]}

Song, Yuhua ^{[7
]}

Wen, Yi ^{[8
]}

Li, Jianbin ^{[2
]}

Jiang, Zefei ^{[2
]}

机构：

[1] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 5, Dept Oncol Ward 4, Beijing 100071, Peoples R China

[2] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 5, Dept Oncol Ward 3, Beijing 100071, Peoples R China

[3] Zhengzhou Univ, Dept Breast Dis, Henan Breast Canc Ctr, Affiliated Canc Hosp, Zhengzhou 450008, Henan, Peoples R China

[4] Henan Canc Hosp, Zhengzhou 450008, Henan, Peoples R China

[5] Nanjing Med Univ, Dept Breast Canc, Jiangsu Prov Hosp, Nanjing 210029, Jiangsu, Peoples R China

[6] Nanjing Med Univ, Dept Breast Canc, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China

[7] Qingdao Univ, Dept Breast Canc Ctr, Affiliated Hosp, Qingdao 260000, Shandong, Peoples R China

[8] Medp Beijing Med Technol Co Ltd, Dept Med, Beijing 100062, Peoples R China

来源：

CHINESE MEDICAL JOURNAL | 2023年 / 136卷 / 12期

关键词：

First-line treatment; Maintenance therapy; TARGETED THERAPY; AMERICAN SOCIETY; TRIAL;

D O I：

10.1097/CM9.0000000000002676

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Endocrine therapy (ET) and ET-based regimens are the preferred first-line treatment options for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HR+/HER2- MBC), while chemotherapy (CT) is commonly used in clinical practice. The aim of this study was to investigate the efficacy and clinical outcome of ET and CT as first-line treatment in Chinese patients with HR+/HER2- MBC. Methods: Patients diagnosed with HR+/HER2-MBC between January 1st, 1996 and September 30th, 2018 were screened from the Chinese Society of Clinical Oncology Breast Cancer database. The initial and maintenance first-line treatment, progression-free survival (PFS), and overall survival (OS) were analyzed. Results: Among the 1877 included patients, 1215 (64.7%) received CT and 662 (35.3%) received ET as initial first-line treatment. There were no statistically significant differences in PFS and OS between patients receiving ET and CT as initial first-line treatment in the total population (PFS: 12.0 vs. 11.0 months, P = 0.22; OS: 54.0 vs. 49.0 months, P = 0.09) and propensity score matched population. For patients without disease progression after at least 3 months of initial therapy, maintenance ET following initial CT (CT-ET cohort, n = 449) and continuous schedule of ET (ET cohort, n = 527) had longer PFS than continuous schedule of CT (CT cohort, n = 406) in the total population (CT-ET cohort vs. CT cohort: 17.0 vs. 8.5 months; P <0.01; ET cohort vs. CT cohort: 14.0 vs. 8.5 months; P <0.01) and propensity score matched population. OS in the three cohorts yielded the same results as PFS. Conclusions: ET was associated with similar clinical outcome to CT as initial first-line treatment. For patients without disease progression after initial CT, switching to maintenance ET showed superiority in clinical outcome over continuous schedule of CT.

引用

页码：1459 / 1467

页数：9

共 30 条

[1]

[Anonymous], 2022, Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer

[2]

[Anonymous], 2003, Cochrane Database Syst Rev, DOI DOI 10.1002/14651858.CD002747

[3] Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer [J].

Bian, Li ;

Xu, Feng-Rui ;

Jiang, Ze-Fei .

CHINESE MEDICAL JOURNAL, 2020, 133 (19) :2338-2345

[4] Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis [J].

Bonotto, Marta ;

Gerratana, Lorenzo ;

Di Maio, Massimo ;

De Angelis, Carmine ;

Cinausero, Marika ;

Moroso, Stefano ;

Milano, Monica ;

Stanzione, Brigida ;

Gargiulo, Piera ;

Iacono, Donatella ;

Minisini, Alessandro Marco ;

Mansutti, Mauro ;

Fasola, Gianpiero ;

De Placido, Sabino ;

Arpino, Grazia ;

Puglisi, Fabio .

BREAST, 2017, 31 :114-120

[5] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J].

Cardoso, F. ;

Paluch-Shimon, S. ;

Senkus, E. ;

Curigliano, G. ;

Aapro, M. S. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. S. ;

Biganzoli, L. ;

Boyle, F. ;

Cardoso, M-J ;

Carey, L. A. ;

Cortes, J. ;

El Saghir, N. S. ;

Elzayat, M. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Gligorov, J. ;

Haidinger, R. ;

Harbeck, N. ;

Hu, X. ;

Kaufman, B. ;

Kaur, R. ;

Kiely, B. E. ;

Kim, S-B ;

Lin, N. U. ;

Mertz, S. A. ;

Neciosup, S. ;

Offersen, B., V ;

Ohno, S. ;

Pagani, O. ;

Prat, A. ;

Penault-Llorca, F. ;

Rugo, H. S. ;

Sledge, G. W. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Wiseman, T. ;

Xu, B. ;

Norton, L. ;

Costa, A. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2020, 31 (12) :1623-1649

[6] Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer [J].

Chen, Xue-Lian ;

Du, Feng ;

Hong, Ruo-Xi ;

Wang, Jia-Yu ;

Luo, Yang ;

Li, Qing ;

Fan, Ying ;

Xu, Bing-He .

CHINESE JOURNAL OF CANCER, 2016, 35

[7] Therapeutic effect of taxanes on metastatic breast cancer of various immunohistochemical subtypes [J].

Fukada, Ippei ;

Araki, Kazuhiro ;

Kobayashi, Kokoro ;

Kobayashi, Takayuki ;

Horii, Rie ;

Akiyama, Futoshi ;

Takahashi, Shunji ;

Iwase, Takuji ;

Ito, Yoshinori .

ONCOLOGY LETTERS, 2016, 12 (01) :663-669

[8] Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis [J].

Giuliano, Mario ;

Schettini, Francesco ;

Rognoni, Carla ;

Milani, Manuela ;

Jerusalem, Guy ;

Bachelot, Thomas ;

De Laurentiis, Michelino ;

Thomas, Guglielmo ;

De Placido, Pietro ;

Arpino, Grazia ;

De Placido, Sabino ;

Cristofanilli, Massimo ;

Giordano, Antonio ;

Puglisi, Fabio ;

Pistilli, Barbara ;

Prat, Aleix ;

Del Mastro, Lucia ;

Venturini, Sergio ;

Generali, Daniele .

LANCET ONCOLOGY, 2019, 20 (10) :1360-1369

[9] The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective [J].

Gupta, Shaloo ;

Zhang, Jie ;

Jerusalem, Guy .

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) :929-940

[10] Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients [J].

Jacquet, E. ;

Lardy-Cleaud, A. ;

Pistilli, B. ;

Franck, S. ;

Cottu, P. ;

Delaloge, S. ;

Debled, M. ;

Vanlemmens, L. ;

Leheurteur, M. ;

Guizard, A. V. ;

Laborde, L. ;

Uwer, L. ;

Jacot, W. ;

Berchery, D. ;

Desmoulins, I. ;

Ferrero, J. M. ;

Perrocheau, G. ;

Courtinard, C. ;

Brain, E. ;

Chabaud, S. ;

Robain, M. ;

Bachelot, T. .

EUROPEAN JOURNAL OF CANCER, 2018, 95 :93-101

← 1 2 3 →